Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

Hagop M. KantarjianTimothy P. HughesRichard A. LarsonDong Wook KimSurapol IssaragrisilPhilipp le CoutreGabriel EtienneCarla BoquimpaniRicardo PasquiniRichard E. ClarkViviane DubruilleIan W. FlinnSlawomira Kyrcz-KrzemienEwa MedrasMaria ZanichelliIsrael BenditSilvia CacciatoreKsenia TitorenkoPaola AimoneGiuseppe SaglioAndreas HochhausSiriraj HospitalSouth Australian Health and Medical Research InstituteSection of Hematology Oncology, The University of ChicagoCHU de NantesSlaski Uniwersytet Medyczny w KatowicachCharité – Universitätsmedizin BerlinRoyal Liverpool University HospitalUniversitätsklinikum Jena und Medizinische FakultätSarah Cannon Research InstituteUniversidade Federal do ParanaUniversity of Texas MD Anderson Cancer CenterUniversità degli Studi di TorinoNovartis International AGThe University of AdelaideUniversidade de São PauloWroclaw Medical UniversityInstitut BergonieThe Catholic University of Korea, College of MedicineNovartis Pharma LLCOncoclínica Rio de JaneiroHemorio2022-08-042022-08-042021-07-01Leukemia. Vol.35, No.7 (2021), 2142-214314765551088769242-s2.0-85107532351https://repository.li.mahidol.ac.th/handle/20.500.14594/76123We found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineCorrection to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)ErratumSCOPUS10.1038/s41375-021-01306-1